Understanding Vitiligo - Causes & Theories April 2011

Vitiligo is a common pigmentary disorder in which the pigment producing cells of the skin (melanocytes) are absent or do not function. As a result, lighter patches of skin appear on various parts of the body due to the lack of melanin (pigment).

The exact cause of vitiligo is still not well understood and many theories exist. In this video we explore established and recent theories that explain the loss of epidermal melanocytes.

We have set up a dedicated vitiligo webpage with information and resources

Visit our blog for guest vitiligo bloggers including Lee Thomas and recent vitiligo news and stories

View more vitiligo videos on our webcast page

Visit out vitiligo article for further information on causes, symptoms, vitiligo types and treatments.

Clinuvel Blog Posts

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

Read More

Clinuvel Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Clinuvel Spotlight

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more